Recurrent Hodgkin's Lymphoma: Prognosis and Symptoms

Advances in the treatment of Hodgkin's lymphoma have resulted in remarkable survival rates, even for diagnoses with advanced unfavorable disease. But for a small percentage of patients, inductive therapy is not enough.

When a patient with Hodgkin's lymphoma has a relapse following induction therapy, he or she is said to have recurrent Hodgkin's lymphoma.

It currently remains unclear why induction therapy fails some patients but works for so many others. Researchers continue to look for biomarkers that may give a clue as to which patients will do well on frontline therapy and which ones will not.

Prognosis

Prognoses for patients with recurrent Hodgkin's lymphoma differ depending on a number of factors. To quote at length from the National Cancer Institute:

Patients who experience a relapse after initial wide-field, high-dose radiation therapy have a good prognosis. Combination chemotherapy results in 10-year disease-free survival (DFS) and overall survival (OS) rates of 57% to 81% and 57% to 89%, respectively. For patients who experience a relapse after initial combination chemotherapy, prognosis is determined more by the duration of the first remission than by the specific induction or salvage combination chemotherapy regimen. Patients whose initial remission after chemotherapy was longer than 1 year (late relapse) have long-term survival with salvage chemotherapy of 22% to 71%. Patients whose initial remission after chemotherapy was shorter than 1 year (early relapse) do much worse and have long-term survival of 11% to 46%.

It is estimated that about 10 percent of Hodgkin's patients will not respond to induction chemotherapy. These patients face high-dose chemotherapy and a stem cell transplant and have less than a 10 percent survival rate eight years following diagnosis.

Symptoms of Recurrent Disease

Some of the symptoms of recurrent Hodgkin's will look and feel very much like the symptoms from a patient's original diagnosis. They include:

  • Night sweats
  • Lymphadenopathy (swollen lymph nodes)
  • Breathing problems
  • Bone aches and pains
  • Lymphoma itching (without a visible rash present)

Following treatment of Hodgkin's lymphoma, all patients need to be aware of the need for follow-up care and should work to develop a survivorship care plan with their physician.

Sources: National Cancer Institute, Leukemia & Lymphoma Society
Photo: Pexels

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap